Evolus Operating Income Over Time
| EOLS Stock | USD 4.30 0.19 4.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Evolus Performance and Evolus Correlation. Is there potential for Pharmaceuticals market expansion? Will Evolus introduce new products? Factors like these will boost the valuation of Evolus. Projected growth potential of Evolus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share | Quarterly Revenue Growth 0.129 | Return On Assets | Return On Equity |
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Evolus' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evolus should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Evolus' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Evolus Inc and related stocks such as Kamada, Oncology Institute, and Treace Medical Concepts Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KMDA | (16.3 M) | (2.3 M) | 4.2 M | 3.7 M | (10.9 M) | (11.4 M) | (5.8 M) | 7.4 M | 19.3 M | 22.8 M | 19.2 M | (696 K) | 4.5 M | 10.1 M | 20.1 M | 23.1 M | 24.2 M |
| TOI | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | (2.6 M) | (8.2 M) | (45.9 M) | (82 M) | (77 M) | (60.1 M) | (54.1 M) | (56.8 M) |
| TMCI | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | 855 K | (16.5 M) | (34.8 M) | (51.4 M) | (55.7 M) | (50.1 M) | (47.6 M) |
| KIDS | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (6.6 M) | (6.1 M) | (6.5 M) | (9.6 M) | (9.1 M) | (26.8 M) | (18 M) | (25.4 M) | (26.8 M) | (29.5 M) | (29 M) | (27.5 M) |
| EHAB | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 102.7 M | 142.9 M | (11.4 M) | (47.6 M) | (115.1 M) | (103.6 M) | (98.4 M) |
| CBLL | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (36 M) | (30 M) | (39.7 M) | (58.4 M) | (61.3 M) |
| NGNE | (10.4 M) | (10.4 M) | (7.7 M) | (9.4 M) | (22.4 M) | (21.3 M) | (37.6 M) | (51.1 M) | (23.5 M) | (24.4 M) | (41.6 M) | (50.5 M) | (56.5 M) | (55.6 M) | (82.6 M) | (74.3 M) | (70.6 M) |
| QSI | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.7 M) | (96.9 M) | (123.8 M) | (111.2 M) | (108.6 M) | (97.7 M) | (102.6 M) |
| AUTL | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (8.1 M) | (14.4 M) | (23.4 M) | (57.5 M) | (247.6 M) | (303.1 M) | (140.4 M) | (142.9 M) | (179.7 M) | (241.4 M) | (217.3 M) | (206.4 M) |
| SLDB | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.6 M) | (54.9 M) | (75.7 M) | (119.3 M) | (86.5 M) | (72.3 M) | (106.5 M) | (104.3 M) | (129.7 M) | (116.8 M) | (122.6 M) |
Evolus Inc and related stocks such as Kamada, Oncology Institute, and Treace Medical Concepts Operating Income description
Operating Income is the amount of profit realized from Evolus Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Evolus Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Evolus Inc | EOLS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 520 Newport Center |
| Exchange | NASDAQ Exchange |
USD 4.3
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.